Regencell Bioscience (NASDAQ:RGC) Shares Up 7.1% – Still a Buy?

Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC) shot up 7.1% during mid-day trading on Tuesday . The company traded as high as $12.00 and last traded at $11.2530. Approximately 156,350 shares were traded during mid-day trading, a decline of 44% from the average daily volume of 280,112 shares. The stock had previously closed at $10.51.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Regencell Bioscience presently has an average rating of “Sell”.

Regencell Bioscience Trading Up 6.0%

The stock’s fifty day moving average is $24.88 and its two-hundred day moving average is $25.80.

Regencell Bioscience (NASDAQ:RGC) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.00) EPS for the quarter.

Institutional Trading of Regencell Bioscience

Hedge funds and other institutional investors have recently modified their holdings of the business. Seven Fleet Capital Management LP acquired a new position in shares of Regencell Bioscience in the 4th quarter valued at approximately $92,000. Amundi purchased a new position in shares of Regencell Bioscience during the 1st quarter valued at approximately $219,000. Hudson Bay Capital Management LP acquired a new stake in shares of Regencell Bioscience during the fourth quarter worth approximately $275,000. Bank of America Corp DE increased its stake in shares of Regencell Bioscience by 59,113.8% in the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after buying an additional 17,143 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Regencell Bioscience in the third quarter worth $598,000. 0.13% of the stock is owned by hedge funds and other institutional investors.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.